Table 3.

Change in outcomes from baseline at 13, 30 and 60 week outcomes in individuals with and without a comorbid anxiety disorder diagnosis within the TTIM and TAU groups

Variable	Baseline	13-weeks	30 weeks	60 weeks	p-value
GAF
TTIM A+	49.9/11.9	59.1/13.0	58.9/12.1	60.5/13.5	0.037
A−	53.4/10.1	60.0/12.0	61.5/14.0	61.6/12.8
TAU A+	50.7/10.8	54.4/11/1	51.4/12.3	54.7/11.5	0.822
A−	52.1/12.8	52.3/13.4	54.7/14.4	52.3/14.5
MADRS
TTIM A+	24.7/10.2	16.6/9.8	19.2/9.7	17.5/9.7	0.075
A−	21.6/8.5	14.4/7.9	15.4/9.3	14.3/10.2
TAU A+	28.3/7.5	23.7/9.4	25.2/9.6	19.6/8.1	0.074
A−	22.3/8.9	19.5/10.1	17.9/9.8	17.8/9.2
BPRS
TTIM A+	40.4/11.0	33.7/11.3	34.3/8.0	32.2/8.5	0.079
A−	37.2/8.5	30.7/6.6	31.9/7.5	31.9/9.6
TAU A+	43.6/8.8	38.7/8.8	38.7/8.2	36.6/9.1	0.263
A−	39.3/8.5	35.4/7.8	34.2/8.8	35.4/8.5
SF-36 Mental Scale
TTIM A+	35.8/10.0	41.4/12.8	37.7/11.7	40.5/10.3	0.020
A−	38.4/11.1	44.4/9.3	43.6/11.4	43.7/11.7
TAU A+	29.8/8.5	36.1/12.4	33.1/11.1	36.8/10.4	0.990
A−	40.8/12.4	40.0/12.1	44.8/11.2	41.5/11.8
SF-36 Physical Scale
TTIM A+	38.3/9.0	38.7/9.8	39.5/9.8	39.7/9.5	0.845
A−	40.3/11.0	41.6/11.1	40.2/12.2	39.6/12.6
TAU A+	41.1/9.3	38.8/8.9	42.0/10.9	41.0/8.3	0.570
A−	38.6/12.1	40.2/10.4	39.2/10.2	40.7/10.0
CGI
TTIM A+	4.5/1.1	3.8/1.2	3.8/1.0	3.3/1.1	0.347
A−	4.5/0.8	3.5/1.1	3.6/1.1	3.2/1.1
TAU A+	4.5/0.8	4.1/1.0	4.4/0.9	4.0/0.9	0.812
A−	4.1/1.0	4.1/1.1	3.9/1.1	4.1/1.3
SDS
TTIM A+	19.8/6.0	15.6/7.5	16.6/6.2	16.0/6.5	0.133
A−	16.3/5.2	12.9/6.0	13.7/8.3	14.1/8.1
TAU A+	19.0/6.0	17.2/6.1	18.6/6.7	16.5/6.6	0.554
A−	16.6/6.7	17.5/7.3	15.8/7.3	16.4/7.6
Hemoglobin A1c
TTIM A+	7.8/2.1	–	7.4/1.7	7.6/1.5	0.030
A−	8.2/2.3	–	8.2/2.7	8.0/2.4
TAU A+	7.8/2.4	–	7.7/2.2	7.9/2.2	0.247
A−	8.1/2.5	–	7.9/1.9	7.6/1.7

(A+: subjects with anxiety disorders

A−: subjects without anxiety disorders)